Oncology News | pharmaphorum

News

Genmab and AbbVie prep filings for lymphoma bispecific

Two years after signing a $3.9 billion alliance with Genmab to find new cancer therapies, AbbVie has said it is ready to start talking to regulators about filing for approval of the lead dr

News

Patient backlog caused by COVID 'could take six years to cle...

The massive backlog in patient care across Europe resulting from the pandemic will take at least three years to clear and in some cases as long as six years, says a new study.

News

AACR: AbbVie says mid-stage trial backs navitoclax in myelof...

AbbVie's BCL-2 inhibitor navitoclax has reported phase 2 results in a trial involving rare and hard-to-treat blood cancer myelofibrosis, eyeing an indication not addressed with Venclexta, i

News

GSK bolsters cancer pipeline with $1.9bn Sierra Oncology buy

GlaxoSmithKline has agreed a deal to buy Sierra Oncology and its lead drug momelotinib for anaemia associated with the blood cancer myelofibrosis, sending the US biotech's shares skywards.<

News

Gilead cleared to restart trials of CD47 drug magrolimab

Gilead Sciences can restart pivotal trials of its cancer antibody magrolimab – the centrepiece of its $4.9 billion

News

AACR: Novartis joins the KRAS clan, eyeing swift move to pha...

Novartis has joined the select cadre of drugmakers developing KRAS inhibitors for cancer, opening its account with phase 1b data on JDQ443 showing efficacy in KRAS-mutated non-small cell lu

Genmab and AbbVie prep filings for lymphoma bispecific

Patient backlog caused by COVID 'could take six years to cle...

AACR: AbbVie says mid-stage trial backs navitoclax in myelof...

GSK bolsters cancer pipeline with $1.9bn Sierra Oncology buy

Gilead cleared to restart trials of CD47 drug magrolimab

AACR: Novartis joins the KRAS clan, eyeing swift move to pha...

Ultomiris fail mars AZ's strong Q2 results

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks